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failure non cachexia group (421.80þ9.14 ng/ml) (P <0.05), (5) the
expression of p85, p-Akt and NF-kB: in cardiac cachexia group was
lower than in the heart failure non cachexia group (P <0.05) and
control group (P <0.05), but the heart failure non cachexia group was
higher than the control group (P <0.05); (6) the expression of caspase9
mRNA: in cardiac cachexia group(1.38þ0.03) was higher than in the
heart failure non cachexia group(0.49þ0.04) and control
group(0.62þ0.07) (P<0.05), (7) the expression of Bcl-xl mRNA: in
cardiac cachexia group (1.39þ0.20) was lower than in the heart failure
non cachexia group(8.03þ0.28) and control group(7.80þ0.15)
(P<0.05).
CONCLUSIONS (1) There were insulin and GH resistance in the heart
failure cachexia patients, (2) PI3K/Akt signal transduction pathways
was activated by phosphorylation in heart failure, which is play a
protective effect on the heart when combined with cachexia. and the
expression of p85, p-Akt and NF-kB were decreased, illustrate that
PI3K/Akt signal pathway was restrained, which eventually lead to cell
apoptosis. (3) PI3K/Akt signal transduction pathway may be a new
therapeutic target in cardiac cachexia.
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OBJECTIVES Renin - angiotensin - aldosterone system (RAAS), by
affecting the nervous hormone levels, involves in the development of
chronic heart failure(CHF). Of interest, for patients with moderate to
severe chronic heart failure, on top of angiotensin-converting enzyme
inhibitors (ACEI) and beta blockers, eplerenone administration will
further reduce the total mortality. However, the therapeutic mecha-
nism for CHF with eplerenone administration is not yet fully
understood.
METHODS Renin - angiotensin - aldosterone system (RAAS), by affecting
the nervous hormone levels, involves in the development of chronic
heart failure(CHF). Of interest, for patients with moderate to severe
chronic heart failure, on top of angiotensin-converting enzyme inhibitors
(ACEI) and beta blockers, eplerenone administration will further reduce
the total mortality. However, the therapeutic mechanism for CHF with
eplerenone administration is not yet fully understood.
RESULTS Compared with conventional treatment, LVEF and 6-min-
ute walk test(6-MWT) distances increased, while LVP, LVEDD, IVS,
TGF-b1 level, BNP level and the blood pressure all reduced in patients
received eplerenone administration (P<0.05), TGF-b1 levels were
inversely correlated with LVEF, and positively correlated with BNP
level (P<0.05).
CONCLUSIONS Eplerenone can reduce plasma TGF-b1 level by
reversing cardiac remodeling and improve cardiac function in chronic
heart failure patients.
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OBJECTIVES Sepsis-related cardiac dysfunction is characterized by
inﬂammation and metabolic repression. microRNAs, a small non-
coding RNA, inhibit mRNA translation or promote mRNA degradation
through pairing to the 3’-UTR of target genes mRNA. MiR155 is up-
regulation as a continual feature of the mammalian inﬂammatory
response. In this study, we tested the hypothesis that miR155 regu-
lates in heart dysfunction with sepsis.
METHODS E.coli lipopolysaccharide (LPS)(5mg/kg) was administered
to C57BL/6 mice to induce a sepsis-induced cardiac dysfunction model
within 5-7 h. Cardiac function was assessed by Echocardiography
5w6h post–LPS administration. Myocardium were obtain within 7w9h
after LPS treatment for gene expression and protein analysis. A
systematic analysis of cardiac miRNA proﬁles using an established
miRNAarray was performed to assess dys-regulated miRNAs in sepsis-
induced cardiac dysfunction. To forced expression of miR155, miR155
agomirs were injected in the tail vein of C57B1/6J mice on 3 consec-
utive days with a total of 30 mg/kg agomir and inhibition of miR155 in
vivo by 80 mg/kg 155 antagomir followed by LPS administration.RESULTS LPS induced reduction 15% in Fractional shortening (%FS)
and 25% in ejection fraction (%EF). Expression of miR155 was
increased by 2 fold. Over-expressing of miR155 with systemic delivery
of agomir led to 5% decrease in FS and 10% in EF as compared to
scramble control. Aggravation of the LPS induced cardiac dysfunction
by miR155 agomir is not associated with alteration in inﬂammation or
cardiac metabolism. MiR155 agomir increased LPS- induced myocar-
dium apoptosis and increased ratio of Bax/Bcl-2 at the protein level.
Deﬁciency of miR155 markedly rescued the LPS induced heart failure
and apoptosis. In vivo, western bloting found that over-expression of
miR155 led to signiﬁcantly inhibition of Pea15a in mice. Using bioin-
formatics analyses and validated luciferase reporter assays, Pea15a
was identiﬁed as a novel miR155-target. Finally, we observed that
critically ill patients with sepsis had increased levels of miR155
compare with healthy control as well.
CONCLUSIONS The present study demonstrated that miR155 regu-
lates sepsis-related cardiac apoptosis by target gene Pea15a. Finally,
our results identify inhibition of miR-34a as a potential therapeutic
strategy to improve sepsis -induced heart failure.GW26-e4801
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OBJECTIVES Chronic heart failure (CHF) is a major public health
burden worldwide and is associated with high morbidity, mortality
and cost. Recent study demonstrated that iron metabolism and
myocardial energy expenditure (MEE) were altered in CHF patients. In
this study, we aimed to analyze the effects, clinical signiﬁcance,
and possible correlations of iron metabolism on MEE in patients with
CHF.
METHODS We recruited 96 CHF patients [age: 67.411.5 years, males:
61.5%, New York Heart Association (NYHA) class (II/III/IV): 45/36/15] from
the Cardiology Department in Nanfang Hospital, Southern Medical Uni-
versity from January 2014 to January 2015. The concentrations of serum
hemoglobin, Fe, total iron-binding capacity, transferrin saturation,
transferrin, soluble transferrin receptor, ferritin, and Pro-BNP were eval-
uated. Echocardiography was used to assess LA, LV, PWTs, LVIDs, LVIDd,
LVEF, LVFS, andMEE. Iron deﬁciency was deﬁned as ferritin <100 ng/mL
or 100-300 ng/mL with transferrin saturation <20%.
RESULTS The patients were divided into iron-deﬁcient and iron-
sufﬁcient groups; the incidence of iron deﬁciency in all subjects was
38.5%. The differences of demographic characteristics (age, sex and
BMI) and HGB concentrations in two groups were similar (P＞0.05).
Interestingly, MEE was signiﬁcantly higher in the iron-deﬁcient group
[64.963 (51.555 to 78.300) cal/min vs. 40.176 (25.346 to 56.914) cal/
min, P＜0.001]. Similarly, MEE in patients with NYHA classes II and III
was signiﬁcantly higher in the iron-deﬁcient group (55.611.4 cal/min
vs. 39.717.5 cal/min, P¼0.002; 63.616.9 cal/min vs. 42.621.0 cal/
min, P¼0.003). Bivariate analysis conﬁrmed that MEE was signiﬁ-
cantly correlated with ferritin (r¼-0.406, P＜0.001), transferrin satu-
ration (r¼-0.307, P¼0.002), Pro-BNP (r¼0.333, P¼0.001), NYHA class
(r¼0.455, P＜0.001), LVEF (r¼-0.477, P＜0.001), LVFS (r¼-0.657, P＜
0.001), LV (r¼0.770, P＜0.001), and LVIDd (r¼0.748, P＜0.001). Mul-
tiple linear regression analysis on the above variables showed that
iron deﬁciency, higher LVIDd, NYHA class, and lower LVFS predicted
higher MEE (r2¼0.748, P＜0.001).
CONCLUSIONS Iron deﬁciency may play an important role in the
disorders of MEE in CHF patients, regardless of baseline HGB con-
centrations.CONGENITAL HEART DISEASE AND INTERVENTIONS
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Prediction of Spontaneous closure in isolated ventricular septal defects by
fetal echocardiography
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OBJECTIVES By conducting a follow-up survey in children who
were diagnosed with simple ventricular septal defect(VSD) in their
mothers’ second trimester through fetal echocardiography, we hope
